Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma

被引：0

作者：

Miguel, Jesus F. San ^{[1
]}

Schlag, Rudolf ^{[2
]}

Khuageva, Nuriet K. ^{[3
]}

Dimopoulos, Meletios A. ^{[4
]}

Shpilberg, Ofer ^{[5
]}

Kropff, Martin H. ^{[6
]}

Spicka, Ivan ^{[7
]}

Petrucci, Maria Teresa ^{[8
]}

Palumbo, Antonio ^{[9
]}

Samoilova, Olga S. ^{[10
]}

Dmoszynska, Anna ^{[11
]}

Abdulkadyrov, Kudrat M. ^{[12
]}

Schots, Rik ^{[13
]}

Jiang, Bin ^{[14
]}

Mateos, Maria-Victoria ^{[15
]}

Anderson, Kenneth C. ^{[16
]}

Esseltine, Dixie-Lee ^{[17
]}

Liu, Kevin ^{[18
]}

Cakana, Andrew ^{[19
]}

van de Velde, Helgi ^{[19
]}

Richardson, Paul

机构：

[1] USAL, CSIC, IBMCC, CIC,Hosp Univ Salamanca, Salamanca, Spain

[2] Praxis Hematol & Oncol, Wurzburg, Germany

[3] SP Botkin Moscow City Clin Hosp, Dept Hematol, Moscow, Russia

[4] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[5] Rabin Med Ctr, Petah Tiqwa, Israel

[6] Univ Munster, Munster, Germany

[7] Charles Univ Praha, Dept Int Med 1, Prague, Czech Republic

[8] Univ Roma La Sapienza, Rome, Italy

[9] Univ Turin, Div Ematol, AOU San Giovanni Battista, Turin, Italy

[10] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[11] Med Univ Lublin, Lublin, Poland

[12] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia

[13] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium

[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA

[17] Takeda Oncol Co, Millennium Pharmaceut, Cambridge, MA USA

[18] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA

[19] Johnson & Johnson Pharmaceut Res & Dev, Dept Clin R&D Oncol, Beerse, Belgium

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：242 / 242

页数：1

共 50 条

[31] Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients
Herbaux, Charles
Joao, Cristina M.
Plocque, Alexia
Richez, Valentine
Gay, Francesca
Renaud, Loic
Legros, Laurence
Garderet, Laurent
Ikhlef, Souhila
Pegourie, Brigitte
Escoffre-Barbe, Martine
Royer, Bruno
Voillat, Laurent
Hulin, Cyrille
Banos, Anne
Voog, Eric G.
Karlin, Lionel
Stoppa, Anne-Marie
Benboubker, Lotfi
Zweegman, Sonja
De Jongh, Eva
Abildgaard, Niels
Le Du, Katell
Jurczyszyn, Artur J.
Moreau, Philippe
Facon, Thierry
Caillot, Denis
Terpos, Evangelos
Leleu, Xavier
BLOOD, 2014, 124 (21)
[32] Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial
Touzeau, Cyrille
Kolb, Brigitte
Hulin, Cyrille
Caillot, Denis
Benboubker, Lotfi
Tiab, Mourad
Leleu, Xavier
Roussel, Murielle
Chaleteix, Carine
Attal, Michel
Facon, Thierry
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
Mateos, Maria-Victoria
San-Miguel, Jesus
Cavo, Michele
Creixenti, Joan Blade
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Dimopoulos, Meletios A.
BLOOD, 2022, 140 : 10157 - 10159
[34] E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
Stewart, A. Keith
Jacobus, Susanna J.
Fonseca, Rafael
Weiss, Matthias
Callander, Natalie Scott
Chanan-Khan, Asher Alban Akmal
Rajkumar, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[35] Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS
Fu, Weijun
Huang, Honghui
Li, Wei
An, Gang
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Qi, Ming
Wang, Jianping
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Hou, Jian
Wang, Jianxiang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S125 - S125
[36] Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Palumbo, Antonio
Bringhen, Sara
Larocca, Alessandra
Rossi, Davide
Di Raimondo, Francesco
Magarotto, Valeria
Patriarca, Francesca
Levi, Anna
Benevolo, Giulia
Vincelli, Iolanda Donatella
Grasso, Mariella
Franceschini, Luca
Gottardi, Daniela
Zambello, Renato
Montefusco, Vittorio
Falcone, Antonietta Pia
Omede, Paola
Marasca, Roberto
Morabito, Fortunato
Mina, Roberto
Guglielmelli, Tommasina
Nozzoli, Chiara
Passera, Roberto
Gaidano, Gianluca
Offidani, Massimo
Ria, Roberto
Petrucci, Maria Teresa
Musto, Pellegrino
Boccadoro, Mario
Cavo, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (07) : 634 - +
[37] E1A06: A PHASE III TRIAL COMPARING MELPHALAN, PREDNISONE, AND THALIDOMIDE (MPT) VERSUS MELPHALAN, PREDNISONE, AND LENALIDOMIDE (MPR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA MM)
Stewart, A. K.
Jacobus, S.
Fonseca, R.
Weiss, M.
Callander, N. S.
Chanan-Khan, A. A.
Rajkumar, S. V.
HAEMATOLOGICA, 2014, 99 : 220 - 220
[38] PHASE I/II STUDY OF CARFILZOMIB PLUS MELPHALAN-PREDNISONE (CMP) IN ELDERLY PATIENTS WITH DE NOVO MULTIPLE MYELOMA
Moreau, P.
Hulin, C.
Caillot, D.
Benboubker, L.
Tiab, M.
Blin, N.
Leleu, X.
Roussel, M.
Chaleteix, C.
Attal, M.
Harousseau, J. L.
Facon, T.
Kolb, B.
HAEMATOLOGICA, 2012, 97 : 116 - 116
[39] INITIAL VERSUS DEFERRED MELPHALAN-PREDNISONE THERAPY FOR ASYMPTOMATIC MULTIPLE-MYELOMA STAGE-I - A RANDOMIZED STUDY
HJORTH, M
HELLQUIST, L
HOLMBERG, E
MAGNUSSON, B
RODJER, S
WESTIN, J
EUROPEAN JOURNAL OF HAEMATOLOGY, 1993, 50 (02) : 95 - 102
[40] Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression
Lopez, Aurelio
Valero, Marta
Lorenzo, Jose Ignacio
Mateos, Maria-Victoria
Oriol, Albert
Joaquin, Martinez
Perez, Montserrat
Martinez, Rafael
de Paz, Raquel
Granell, Miguel
De Arriba, Felipe
Blanchard, M. Jesus
Javier Penalver, Francisco
Bello, Jose Luis
Martin, Maria Luisa
Bargay, Joan
Blade, Joan
Lahuerta, Juan Jose
San Miguel, Jesus F.
De La Rubia, Javier
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →